RxDoctor Payments Data

Gary Friedman, MD

Cardiovascular Disease · Roslyn, NYNPI 1518046333

Payments from drug & device makers

$793in general payments, 2019–2025

Across 36 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$225
  • E.r. Squibb & Sons, L.L.C.$133
  • Novartis$124
  • Lilly USA, LLC$86
  • Pfizer$39
  • Impulse Dynamics (USA) Inc.$38
  • plus $149 from 5 others

What the payments were for

  • Food & beverage$793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$793 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$325,406
Medicare patients
989
Services billed
3,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban314$385,608
EliquisApixaban335$339,685
EntrestoSacubitril/Valsartan207$238,952
Repatha SureclickEvolocumab84$60,612
BrilintaTicagrelor47$42,252
FarxigaDapagliflozin Propanediol31$29,344
NexletolBempedoic Acid30$25,710
Ezetimibe544$16,136
Praluent PenAlirocumab21$14,976
Metoprolol Succinate647$10,578
Rosuvastatin Calcium676$10,050
Prasugrel Hcl101$7,568
JardianceEmpagliflozin12$7,212
Atorvastatin Calcium618$6,801
Nebivolol Hcl80$6,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$339,685335 claims
NovartisEntresto$124$238,952207 claims
Esperion Therapeutics, Inc.Nexletol$37$25,71030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →